If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
67
results.
Updated on
15/07/2026 [08:21:00]
Results 50 to 67 of 67
Absstract of: CN121801908A
The invention belongs to the technical field of biology, and particularly relates to a CFTSR gene, a CFTSR gene simulant and application of the CFTSR gene simulant. The nucleic acid sequence of the CFTSR gene is as shown in SEO ID NO. 1. The nucleic acid sequence of the CFTSR gene simulant is as shown in SEO ID NO. 2. The CFTSR gene provided by the invention can be used as a marker for fibroblast activation, and is used for a kit for detecting cardiac fibroblast activation. The CFTSR gene simulant can be used as a therapeutic drug for myocardial infarction injury, and the overexpression of the CFTSR gene can significantly inhibit the proliferation of fibroblasts and activate the repair of damaged myocardial tissues. Based on CFTSR mimics, a simulant of the CFTSR gene is constructed, and the simulant can be conveyed to the position of a heart lesion and can be used as a medicine for treating myocardial infarction injury, so that effective treatment of the lesion is realized.
Absstract of: CN121796597A
The invention discloses application of an STAT1 inhibitor and a detection preparation and a construction method of a vascular transplantation remodeling model, and belongs to the technical field of transplantation vascular remodeling treatment and diagnosis. The STAT1 is used as a target spot for preventing, treating and/or relieving the transplanted vascular remodeling and related diseases, meanwhile, the STAT1 is used as a biomarker for diagnosing the transplanted vascular remodeling, and a new thought is provided for preventing, treating and/or relieving the transplanted vascular remodeling and the related diseases.
Absstract of: CN121802037A
The invention discloses pharmaceutical application of RNA helicase DHX8, including application of the RNA helicase DHX8 in aortic dissection diagnosis, treatment and drug development. It is found for the first time that DHX8 is significantly down-regulated in aortic dissection patients, animal models and vascular endothelial cells, and overexpression of DHX8 can effectively up-regulate endothelial cell tight connection related genes and repair the endothelial barrier function. The Si DHX8 is used for transfecting human umbilical vein endothelial cells (HUVECs), and the DHX8 is knocked down, so that the tight connection gene OCLN is obviously reduced; when the OE DHX8 plasmid is used for transfecting the HUVECs and overexpressing the DHX8, the tight connection genes OCLN, JAM-A, ZO-1 and VE-cadherin are found to be obviously up-regulated. The DHX8 is used as a new target for aortic dissection diagnosis and treatment, and a detection reagent, a gene therapy vector and an agonist drug of the DHX8 have important clinical transformation values.
Absstract of: KR20260045555A
본 발명은 메틸화 바이오마커를 기반 심근경색의 진단, 예측 또는 모니터링 방법에 관한 것으로, 심근경색 환자군에서 차별적으로 변화된 메틸화 수준을 나타내는 특정 메틸화 마커 및 유전자를 발굴하였으므로, 심근경색을 조기에 객관적으로 예측, 진단, 모니터링 및 예후를 평가하는데 유용하게 이용될 수 있다.
Absstract of: CN121780679A
The invention belongs to the field of biological medicine, and particularly relates to a YBX3 gene, a YBX3 gene inhibitor and application of the YBX3 gene inhibitor. The invention discloses application of the YBX3 gene as a biomarker in preparation of a product for detecting cardiac fibrosis. The nucleotide sequence of the YBX3 gene is as shown in SEQ ID NO. 1. The invention discloses application of a YBX3 gene inhibitor in preparation of drugs for preventing and/or treating heart diseases. The YBX3 gene inhibitor is shRNA (short hairpin ribonucleic acid) and has a nucleotide sequence as shown in SEQ ID NO. 3. When myocardial infarction occurs, mRNA and protein level expression activity of the YBX3 gene is remarkably improved and is related to fibroblast activation, and the silent YBX3 gene can remarkably inhibit fibroblast activation. The existing myocardial infarction injury medicine has a limited treatment effect, so that the YBX3 can improve the clinical prognosis of myocardial infarction injury by regulating and controlling the activation of cell fibrosis.
Absstract of: CN121789763A
The invention discloses a method, a system and equipment for predicting sensitivity of a patient with vascular remodeling lesion caused by circadian rhythm disorder to targeted IRF1 treatment. The invention discovers that circadian rhythm regulates inflammatory response of a body through IRF1 to cause vascular remodeling lesion for the first time, which prompts that a targeted IRF1 treatment method can be adopted for a patient with vascular remodeling caused by circadian rhythm disorder, so that a clinician is guided to formulate an individualized treatment scheme for the patient.
Absstract of: AU2026201866A1
Methods and compositions are provided for detecting a predisposition for cardiovascular disease in an individual. disease in an individual. ar a r d i s e a s e i n a n i n d i v i d u a l
Absstract of: CN121759597A
The invention provides a human venous thrombosis risk gene polymorphism detection primer probe composition as well as preparation and application thereof, and belongs to the technical field of nucleic acid detection methods. The primer probe composition comprises the following sequences: a primer pair PAI-1-F and PAI-1-R which are used for detecting the PAI-14G/5G site and are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2, and a probe PAI-1-P of which the sequence is shown as SEQ ID NO: 3; the probe is used for detecting PROCc.565Cgt; the primer pair of the T site PROC (565 Cgt; t)-F and PROC (565 Cgt; the invention relates to a kit for detecting the content of procyanidine, in particular to a kit for detecting the content of procyanidine, which comprises a probe PROC (565Cgt, T)-R and a probe PROC (565Cgt; t)-P, the sequence of which is as shown in SEQ ID NO: 6; the detection kit is used for detecting MTHFRc.677Cgt; the sequences of the primer pair MTHFR-F and MTHFR-R of the T site are respectively shown as SEQIDNO: 7 and SEQIDNO: 8, and the sequence of the probe MTHFR-P is shown as SEQIDNO: 9; wherein the 5'end of the probe is marked with a fluorophore, the 3 'end of the probe is marked with a quenching group, and the first three basic groups are modified by phosphoric acid. The kit is high in detection sensitivity.
Absstract of: CN121759593A
The invention discloses a biomarker for treating post-stroke depression and application thereof, and belongs to the technical field of biomedicine. The biomarker is a micro ribonucleic acid-146 (miR-146) family member, and specifically comprises miR146b (micro ribonucleic acid)-3p, miR146a (micro ribonucleic acid)-5p, miR146a (micro ribonucleic acid)-3p and miR146b (micro ribonucleic acid)-5p. Experiments prove that the expression of miR146b-3p and miR146a-5p in hippocampal tissues of mice in a PSD state is up-regulated, the expression of miR146a-3p and miR146b-5p is down-regulated, and the expression of the subtypes can be regulated to a normal level by using radix bupleuri liver soothing powder (CSS). The biomarker can be used for PSD diagnosis, illness state evaluation and treatment effect monitoring, provides a target spot for screening and research and development of PSD treatment drugs, and has important clinical application value and scientific research significance.
Absstract of: CN121731470A
The invention discloses application of sFRP2 in preparation of a medicine for treating ischemic heart failure by inhibiting a Wnt/beta-catenin signal channel, a related kit and a medicine screening method, relates to the technical field of biological medicines, and discloses application of sFRP2 in preparation of a medicine for treating heart failure caused by ischemic cardiomyopathy by inhibiting the Wnt/beta-catenin signal channel. The medicine comprises an effective dose of sFRP2 protein; the medicine is characterized by comprising a Wnt/beta-catenin signal channel inhibitor, the invention relates to a kit for evaluating the risk of ischemic heart failure. The kit comprises a reagent for detecting the expression level of sFRP2 and Wnt/beta-catenin; the invention relates to an application in a medicine for treating ischemic heart failure by inhibiting a Wnt/beta-catenin signal channel, a related kit and a medicine screening method, which are used for developing a new treatment medicine and improving the treatment effect of the ischemic heart failure. Meanwhile, the invention provides a kit for evaluating the risk of ischemic heart failure, and early and accurate diagnosis and risk evaluation of the disease are realized.
Absstract of: CN121731448A
The invention discloses application of INO80E in preparation of an anti-atherosclerosis medicine, and belongs to the technical field of biological medicines. The invention reveals for the first time that INO80E can interact with histone deacetylase 1 (HDAC1) so as to deacetylate a transcription factor YY1, so that vascular endothelial cell apoptosis is inhibited, and the purpose of delaying an atherosclerosis process is achieved. Experiments prove that the expression level of INO80E in an atherosclerosis model is remarkably reduced; overexpression of INO80E can effectively reverse endothelial cell apoptosis induced by oxidized low-density lipoprotein (ox-LDL) and restore expression balance of anti-apoptotic protein Bcl-2 and pro-apoptotic protein BAX. Therefore, the INO80E can be used as a brand new drug target for treating or preventing atherosclerosis related diseases, can be used for preparing diagnostic reagents or drugs, and has the advantages of no equipment dependence and strong targeting.
Absstract of: CN121718626A
The invention relates to the technical field of biological medicine, in particular to a marker for diagnosis and treatment of heart failure and application of the marker, and aims to solve the problem that in the prior art, systematic and deep research on CTHRC1 in a pressure overload model closer to human heart failure pathology is lacked. The application proves that the expression level of the CTHRC1 is obviously up-regulated no matter in heart tissues and serum of an animal model or serum of a clinical sample, so that the reliability and the sensitivity of the CTHRC1 as the heart failure biomarker are proved, and a brand-new diagnostic marker directly related to fibrosis pathology is provided for the heart failure; in addition, it is also clearly proposed that the CTHRC1 monoclonal antibody is used for preparing a medicine for treating heart failure, and the CTHRC1 monoclonal antibody can neutralize and effectively block the specific biological function activity of a CTHRC1 immunogen through high binding affinity, and can become a new treatment target for relieving or reversing cardiac fibroblast activation and cardiac fibrosis.
Absstract of: CN121718536A
The invention belongs to the technical field of biological medicine. More specifically, the invention provides the annular RNACircMAP2, and the sequence of the annular RNACircMAP2 is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. The invention proves that CircMAP2 can be used as a novel biomarker for diagnosing acute ischemic stroke for the first time. Compared with a traditional imaging diagnosis method, the acute ischemic stroke can be diagnosed by detecting the expression level of the CircMAP2 in the plasma and the plasma exosome of the patient, the cerebral infarction area of the acute ischemic stroke can be speculated through the expression level of the CircMAP2, and the method has the advantages of being easy and convenient to operate, high in detection speed and low in cost; the system is especially suitable for popularization and use in primary medical institutions. The product for diagnosing acute ischemic stroke provided by the invention can quickly and accurately diagnose acute ischemic stroke, and has good clinical popularization prospect and application value.
Absstract of: CN121700057A
The invention discloses an SNP (Single Nucleotide Polymorphism) marker combination for evaluating venous thromboembolism, a product and application, and relates to the technical field of in-vitro detection. The invention discloses an SNP (Single Nucleotide Polymorphism) marker combination, which comprises an rs201381904, an rs587776397, an rs146922325, an rs199469469, an rs199469503, an rs1576170616, an rs121918474, an rs2107279407, an rs1799762, an rs16984852 and an rs1801133, and is characterized in that the rs587776397, the rs146922325, the rs199469469, the rs199469503, the rs1576170616, the The SNP marker combination covers a plurality of physiological pathways such as coagulation, anticoagulation, fibrinolysis, folic acid metabolism and the like, and compared with the prior art that only a few loci are detected, evaluation is more comprehensive. The detection method provided by the invention can be realized based on a mature PCR technology, and is easy to popularize and apply in a clinical examination laboratory.
Absstract of: WO2026057057A1
Provided are a group of biomarkers for diagnosing hypertension in children, a test kit, and a use thereof. By means of collecting tongue coating/intestinal samples of obese children with hypertension, obese children, and healthy people, performing metagenomic sequencing, and using bioinformatics to calculate statistics on sequencing data, disease-related tongue/intestinal flora is found, and the tongue/intestinal flora is integrated with disease information to obtain a combination of flora biomarkers. A binary classification prediction model constructed by means of said combination can maximally detect obese children with hypertension.
Absstract of: WO2026055844A1
A system for early warning of coronary heart disease. A computer device comprises a memory, a processor, and a computer program stored on the memory. The processor executes the computer program to implement the following steps: receiving methylation level data of a DNA methylation marker combination of a potential coronary heart disease patient and a healthy control sample, establishing a mathematical model, and determining a threshold; and inputting methylation level data of the DNA methylation marker combination of a subject to be tested and substituting same into the mathematical model to obtain a detection index, and comparing the detection index with the threshold to obtain a conclusion of whether a sample to be tested belongs to the potential coronary heart disease patient or the healthy control. The present invention has important scientific significance and clinical application value in early warning of coronary heart disease and diagnosis and treatment of coronary heart disease.
Nº publicación: CN121687206A 17/03/2026
Applicant:
HUNAN QINGGENG BIOLOGICAL INDUSTRY INNOVATION RESEARCH INST CO LTD
\u6E56\u5357\u7701\u9752\u8015\u751F\u7269\u4EA7\u4E1A\u521B\u65B0\u7814\u7A76\u9662\u6709\u9650\u516C\u53F8
Absstract of: CN121687206A
The invention discloses a microRNA (Ribonucleic Acid) prediction model and a prediction kit for identifying myocardial infarction. According to the invention, six microRNAs with stable and specific expression modes in peripheral blood of an AMI patient are taken as combined markers and are used for identifying the onset risk of AMI. The microRNAs may have abnormal expression before myocardial infarction attack, have good detection stability in blood, and are important supplements for myocardial necrosis markers such as traditional troponin and the like. By capturing the early expression change of microRNA in peripheral blood, high-risk individuals can be subjected to prospective identification before typical symptoms appear, and a time window is provided for active intervention.
BOPI
Electronic site
